On October 3, 2024 press releases titled "Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of ...
Q3 2024 net loss totaled $8.8 million compared to a net loss of $1.8 million in the prior year period, which was primarily the result of lower net sales and higher other expenses due to the change in ...